Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. more
Time Frame | RNAC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -28.88% | -2.06% | -0.55% |
1-Month Return | -8.89% | -1.92% | 2.72% |
3-Month Return | 8.25% | -10.4% | 7.66% |
6-Month Return | -22.24% | -4.6% | 10.15% |
1-Year Return | -22.65% | 4.06% | 27.53% |
3-Year Return | -82.75% | 1.94% | 32.31% |
5-Year Return | -61.37% | 36.48% | 89.2% |
10-Year Return | -95.97% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 6.68M | 16.60M | 85.08M | 110.78M | 26.00M | [{"date":"2019-12-31","value":6.03,"profit":true},{"date":"2020-12-31","value":14.98,"profit":true},{"date":"2021-12-31","value":76.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":23.47,"profit":true}] |
Cost of Revenue | 42.74M | - | - | 2.04M | 1.55M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":4.77,"profit":true},{"date":"2023-12-31","value":3.63,"profit":true}] |
Gross Profit | 6.68M | 16.60M | 85.08M | 108.74M | 24.45M | [{"date":"2019-12-31","value":6.14,"profit":true},{"date":"2020-12-31","value":15.26,"profit":true},{"date":"2021-12-31","value":78.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.49,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 98.16% | 94.03% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.16,"profit":true},{"date":"2023-12-31","value":94.03,"profit":true}] |
Operating Expenses | 57.10M | 73.42M | 89.67M | 96.24M | 110.87M | [{"date":"2019-12-31","value":51.51,"profit":true},{"date":"2020-12-31","value":66.22,"profit":true},{"date":"2021-12-31","value":80.88,"profit":true},{"date":"2022-12-31","value":86.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (52.45M) | (56.82M) | (4.60M) | 14.54M | (86.42M) | [{"date":"2019-12-31","value":-360.81,"profit":false},{"date":"2020-12-31","value":-390.84,"profit":false},{"date":"2021-12-31","value":-31.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-594.41,"profit":false}] |
Total Non-Operating Income/Expense | (4.41M) | (13.61M) | (7.97M) | 17.20M | (155.13M) | [{"date":"2019-12-31","value":-25.66,"profit":false},{"date":"2020-12-31","value":-79.13,"profit":false},{"date":"2021-12-31","value":-46.32,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-901.85,"profit":false}] |
Pre-Tax Income | (55.35M) | (68.88M) | (9.72M) | 34.77M | (238.71M) | [{"date":"2019-12-31","value":-159.19,"profit":false},{"date":"2020-12-31","value":-198.09,"profit":false},{"date":"2021-12-31","value":-27.96,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-686.54,"profit":false}] |
Income Taxes | 1.86M | 1.65M | 15.97M | (609.00K) | (19.00M) | [{"date":"2019-12-31","value":11.62,"profit":true},{"date":"2020-12-31","value":10.3,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.81,"profit":false},{"date":"2023-12-31","value":-119,"profit":false}] |
Income After Taxes | (57.21M) | (70.52M) | (25.69M) | 35.38M | (219.71M) | [{"date":"2019-12-31","value":-161.69,"profit":false},{"date":"2020-12-31","value":-199.33,"profit":false},{"date":"2021-12-31","value":-72.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-621.02,"profit":false}] |
Income From Continuous Operations | (55.35M) | (68.88M) | (25.69M) | 35.38M | (219.71M) | [{"date":"2019-12-31","value":-156.45,"profit":false},{"date":"2020-12-31","value":-194.68,"profit":false},{"date":"2021-12-31","value":-72.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-621.02,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (55.35M) | (68.88M) | (25.69M) | 35.38M | (219.71M) | [{"date":"2019-12-31","value":-156.45,"profit":false},{"date":"2020-12-31","value":-194.68,"profit":false},{"date":"2021-12-31","value":-72.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-621.02,"profit":false}] |
EPS (Diluted) | (1.24) | (0.69) | (0.31) | 0.28 | (0.34) | [{"date":"2019-12-31","value":-442.86,"profit":false},{"date":"2020-12-31","value":-246.43,"profit":false},{"date":"2021-12-31","value":-110.71,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-121.43,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RNAC | |
---|---|
Cash Ratio | 10.24 |
Current Ratio | 10.70 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RNAC | |
---|---|
ROA (LTM) | -10.95% |
ROE (LTM) | -7029.26% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RNAC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.00 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.00 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RNAC | |
---|---|
Trailing PE | NM |
Forward PE | 25.45 |
P/S (TTM) | 8.97 |
P/B | 572.17 |
Price/FCF | 57 |
EV/R | 4.71 |
EV/Ebitda | NM |
PEG | NM |
Cartesian Therapeutics Inc. (RNAC) share price today is $16.92
Yes, Indians can buy shares of Cartesian Therapeutics Inc. (RNAC) on Vested. To buy Cartesian Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNAC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cartesian Therapeutics Inc. (RNAC) via the Vested app. You can start investing in Cartesian Therapeutics Inc. (RNAC) with a minimum investment of $1.
You can invest in shares of Cartesian Therapeutics Inc. (RNAC) via Vested in three simple steps:
The 52-week high price of Cartesian Therapeutics Inc. (RNAC) is $41.87. The 52-week low price of Cartesian Therapeutics Inc. (RNAC) is $11.66.
The price-to-earnings (P/E) ratio of Cartesian Therapeutics Inc. (RNAC) is
The price-to-book (P/B) ratio of Cartesian Therapeutics Inc. (RNAC) is 572.17
The dividend yield of Cartesian Therapeutics Inc. (RNAC) is 0.00%
The market capitalization of Cartesian Therapeutics Inc. (RNAC) is $430.27M
The stock symbol (or ticker) of Cartesian Therapeutics Inc. is RNAC